Key result
PASCAL Ace yields ~99% procedural success in severe mitral regurgitation, reducing MR to ≤1 in most.
Why the study?
The functional and hemodynamic outcomes after transcatheter edge-to-edge repair with the newer PASCAL Ace device in a real-world cohort were not well characterized.
Cohort (n=66)
No
Supports PASCAL Ace feasibility in severe MR; leaves open durability and randomized comparisons before practice change.
OBJECTIVES: The PASCAL device is a transcatheter edge-to-edge repair system (TEER) for treatment of mitral regurgitation (MR). The PASCAL Ace as a newer version of the PASCAL device consists of a thinner profile without a spacer. The aim of the study was to examine the functional and hemodynamic outcome after TEER with the PASCAL Ace device in a real-world cohort. METHODS: Between September 2020 and August 2021, all consecutive patients with MR 3+/4+ treated percutaneously with PASCAL Ace were included in this study. Primary endpoints included successful device implantation, device success, improvement of exercise capacity, quality of life, and a composite of all-cause mortality, non-fatal stroke, myocardial infarction, new need for renal replacement therapy or severe bleeding at 30 days and 5 month. RESULTS: 49/66 patients had a functional etiology. Overall success rate was 98.5%. At follow-up, 84.7% of the patients had MR grade ≤ 1. TEER was associated with an improvement of LV ejection fraction (45% to 53%, p = 0.048). 86.5% were in NYHA class I or II. 6-minute-walking distance improved by 79m (p = 0.009). Kansas City Cardiomyopathy Questionnaire (KCCQ) improved by 19 points (p = 0.012). NT-proBNP levels decreased from 4832 to 2137 pg/dl (p = 0.003). Mean pulmonary capillary wedge pressures improved from 21 to 15mmHg (p = 0.001). At 5 month, a total of 3 patients died, none of cardiovascular cause. CONCLUSION: PASCAL Ace is safe and effective in treating MR, resulting in a sustained MR reduction, a reverse cardiac remodelling, improvement of exercise capacity, quality of life, NT-proBNP levels and hemodynamics at follow-up.
No takes yet. Share an insight, caveat, or question.
Barth et al. (2022) conducted a cohort in Mitral regurgitation (MR 3+/4+) (n=66). PASCAL Ace percutaneous mitral valve repair was evaluated on Successful device implantation, device success, improvement of exercise capacity, quality of life, and a composite of all-cause mortality, non-fatal stroke, myocardial infarction, new need for renal replacement therapy or severe bleeding at 30 days and 5 months. Treatment with the PASCAL Ace device in patients with severe mitral regurgitation resulted in an overall success rate of 98.5%, with 84.7% achieving MR grade ≤1 at follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: